[Molecular genetics of gliomas].
Gliomas represent the majority of primary central nervous system tumors in adults. The moderate overall impact of conventional therapeutic regimens on these inherently aggressive neoplasms raises the need for a direct intervention in the biology of neoplastic change. In the last decade important achievements in the molecular genetic basis of deregulated cell-cycle have been brought about, the neuro-oncologic implications of which are reviewed here. Loss of equilibrium between promoting factors and negative control of mitosis emergeus as a general principle, with gene amplification-overexpression operating in the former group, while deletions, loss of function-type mutations and post-transcriptional events prevail at the opposite pole. Damage to regulatory mechanisms will result, as a major consequence, in transgression of one or more of the so-called restriction points of the cell-cycle. Lesions of the genome are further ramified by supracellular processes involving autocrine and paracrine growth-stimulating loops. Malignant progression of gliomas, therefore, can be envisaged as a cumulative sequence of genetic alterations and interactions of tumor cells with their microenvironment.
Vajtai
I
I
Neues Allgemeines Krankenhaus Wien, Neuropathologiai Intézet.
Varga
Z
Z
D000328:Adult; D001254:Astrocytoma / Q000235:genetics; D002453:Cell Cycle; D004806:Ependymoma / Q000235:genetics; D005260:Female; D016147:Genes, Tumor Suppressor; D005910:Glioma / Q000235:genetics*; D006133:Growth Substances; D006801:Humans; D008297:Male; D008967:Molecular Biology; D009837:Oligodendroglioma / Q000235:genetics
D006133:Growth Substances
A gliomák molekuláris genetikája.